<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: Risks of <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>) following <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B and/or <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C virus (HBV/HCV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> are well known, those for other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are less well understood </plain></SENT>
<SENT sid="1" pm="."><plain>The aim was to quantify the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> among persons diagnosed with HBV/HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The data from a cohort of 39109 HBV, 75834 HCV, and 2604 HBV/HCV co-infected persons notified to the State health department, 1990-2002, were probabilistically linked to the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry and standardised incidence ratios (SIRs) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> were calculated </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The match rate for any <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 2.7%, 2.3% and 3.3% for HBV, HCV and HBV/HCV co-infected notifications </plain></SENT>
<SENT sid="4" pm="."><plain>SIRs for <z:mp ids='MP_0003331'>HCC</z:mp> were 30.6 (95% CI 25.7-36.5), 22.7 (95% CI 19.1-26.5) and 30.3 (95% CI 13.6-67.5), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Increased risk was detected for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and HBV (SIR 12.9, 95% CI 5.4-30.9) and immunoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> following HCV (SIR 5.6, 95% CI 1.8-17.5) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The risk of <z:mp ids='MP_0003331'>HCC</z:mp> in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The modest though significant risk of immunoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> associated with HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> is consistent with recent findings </plain></SENT>
</text></document>